medigraphic.com

2023, Number 2

<< Back Next >>

Rev Educ Bioquimica 2023; 42 (2)

Cronoterapias dirigidas a las principales enfermedades crónicas en México

Ávila ROS, Espinosa AJJ, Camacho CR

Language: Spanish
References: 35
Page: 87-98
PDF size: 661.85 Kb.


ABSTRACT

In Mexico, 80% of the population over 50 suffers from some chronic disease. Multiple reports suggest that most pathologies present a climax in 24-h periods in which the clinical manifestations are more severe. This has been the starting point for determining times for the administration of drugs, which is called chronotherapy. This paper reviews the current panorama of chronotherapies for different chronic diseases.


REFERENCES

  1. 1.Chaudhari A, Gupta R, Makwana K,Kondratov R. Circadian clocks, diets andaging. J Nutr Health Aging. 2017;4(2):101–112.https://doi.org/10.3233/NHA-160006

  2. 2.Chaix A, Zarrinpar A, Panda S. The circadiancoordination of cell biology. JCB.2017;215(1):15–25.https://doi.org/10.1083/jcb.201603076

  3. 3.Arellanes-Licea E, Caldela I, De Ita-Pérez D,Díaz-Muñoz M. The circadian timing system:a recent addition in the physiologicalmechanisms underlying pathological andaging processes. Aging Dis. 2014;5(6):406–418.https://doi.org/10.14336/AD.2014.0500406

  4. 4.Lee Y, Field JM, Sehgal A. Circadian Rhythms,Disease and Chronotherapy. J. Biol.Rhythms. 2021;36(6):503–531.https://doi.org/10.1177/07487304211044301

  5. 5.Clark NM. Management of chronic disease bypatients. Annu. Rev. Public Health.2003;24:289–313.https://doi.org/10.1146/annurev.publhealth.24.100901.141021

  6. 6.El INEGI presenta resultados de la quintaedición de la encuesta nacional de salud yenvejecimiento [internet]. INEGI comuni-cado de prensa núm. 450/20. 1 de octubrede 2020 [23 de abril 2023] [28 p.] Disponibleen:https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2020/ENASEM/Enasem_Nal20.pdf

  7. 7.Estadísticas a propósito del día mundialcontra el cáncer (4 de febrero) datosnacionales [internet]. INEGI comunicado deprensa núm. 74/22. 2 de febrero de 2022[23 de abril 2023] [5 p.] Disponible en:https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2022/EAP_CANCER22.pdf

  8. 8.Polishchuk NA. Chronotherapy and relativitytheory. Likars'ka sprava. 2008;(1-2):113–118.

  9. 9.Honma S. The mammalian circadian system:a hierarchical multi-oscillator structure forgenerating circadian rhythm. J Physiol Sci.2018;68(3):207–219.https://doi.org/10.1007/s12576-018-0597-5

  10. 10.Dunlap JC. Molecular bases for circadianclocks. Cell. 1999;96(2):271–290.https://doi.org/10.1016/s0092-8674(00)80566-8

  11. 11.Skene DJ, Skornyakov E, Chowdhury NR,Gajula RP, Middleton B, Satterfield BC, PorterKI, Van Dongen H, Gaddameedhi S.Separation of circadian- and behavior-drivenmetabolite rhythms in humans provides awindow on peripheral oscillators andmetabolism. PNAS USA. 2018;115(30):7825–7830.https://doi.org/10.1073/pnas.1801183115

  12. 12.Torday JS. Homeostasis as the Mechanism ofEvolution. Biol. 2015;4(3):573–590.https://doi.org/10.3390/biology4030573

  13. 13.Aguilar-Roblero R, Díaz-Muñoz M.Chronostatic adaptations in the liver torestricted feeding: The FEO as an emergentoscillator. Sleep Biol Rhythms. 2010;8:9-17.https://doi:10.1111/j.1479-8425.2009.00415.x

  14. 14.Dallmann R, Okyar A, Lévi F. Dosing-TimeMakes the Poison: Circadian Regulation andPharmacotherapy. Trends Mol Med.2016;22(5):430–445.https://doi.org/10.1016/j.molmed.2016.03.004

  15. 15.Ohdo S. Chronotherapeutic strategy:Rhythm monitoring, manipulation anddisruption. Adv. Drug Deliv. Rev. 2010;62(9-10):859–875.https://doi.org/10.1016/j.addr.2010.01.006

  16. 16.Ohdo S, Koyanagi S, Matsunaga N.Chronopharmacological strategies focusedon chrono-drug discovery. Pharmacol. Ther.2019;202:72–90.https://doi.org/10.1016/j.pharmthera.2019.05.018

  17. 17.Smith DF, Ruben MD, Francey LJ, Walch OJ,Hogenesch JB. When Should You Take YourMedicines? J. Biol. Rhythms.2019;34(6):582–583.https://doi.org/10.1177/0748730419892099

  18. 18.Hodgson E. A textbook of modern toxicology3ra Edición. USA: Jhon Wiley & Sons, INC.,Publication; 2004

  19. 19.Baojian W. Danyi L. Dong D. Circadianpharmacokinetics 3ra Edición. Singapure:Springer; 2020

  20. 20.Prkacin I, Balenovic D, Djermanovic-DobrotaV, Lukac I, Drazic P, Pranjic IK. Resistanthypertension and chronotherapy. MaterSociomed. 2015;27(2):118–121.https://doi.org/10.5455/msm.2015.27.118-121

  21. 21.Hermida RC, Ayala DE, Fernández JR, MojónA, Smolensky MH, Fabbian F, Portaluppi F.Administration-time differences in effects ofhypertension medications on ambulatoryblood pressure regulation. Chronobiol. Int.2013;30(1-2):280–314.https://doi.org/10.3109/07420528.2012.709448

  22. 22.Tadic M, Cuspidi C, Grassi G, Mancia G.Isolated Nocturnal Hypertension: What DoWe Know and What Can We Do? Integr BloodPress Control. 2020;13:63–69.https://doi.org/10.2147/IBPC.S223336

  23. 23.Stranges PM, Drew AM, Rafferty P, ShusterJE, Brooks AD. Treatment of hypertensionwith chronotherapy: is it time of drugadministration? Ann Pharmacother.2015;49(3):323–334.https://doi.org/10.1177/1060028014563535

  24. 24.Hermida RC, Ayala DE, Smolensky MH,Fernández JR, Mojón A, Portaluppi F.Chronotherapy with conventional bloodpressure medications improves managementof hypertension and reduces cardiovascularand stroke risks. Hypertens. Res.: JSH.2016;39(5):277–292.https://doi.org/10.1038/hr.2015.142

  25. 25.Sparks JA. Rheumatoid Arthritis. Ann.Intern. Med. 2019;170(1):ITC1–ITC16.https://doi.org/10.7326/AITC201901010

  26. 26.Cutolo M. Circadian rhythms and rheumatoidarthritis. Jt. Bone Spine. 2019;86(3):327–333.https://doi.org/10.1016/j.jbspin.2018.09.003

  27. 27.Cutolo M. Glucocorticoids and chronotherapyin rheumatoid arthritis. RMD open.2016;2(1):e000203.https://doi.org/10.1136/rmdopen-2015-000203

  28. 28.American Diabetes Association. Diagnosisand classification of diabetes mellitus.Diabetes care, 2014; 37 (Suppl 1), S81–S90.https://doi.org/10.4158/EP12042.OR

  29. 29.King AB, Clark D, Wolfe GS. Contribution ofthe dawn phenomenon to the fasting andpostbreakfast hyperglycemia in type 1diabetes treated with once-nightly insulinglargine. Endocr Pract. 2012;18(4):558–562.https://doi.org/10.4158/EP12042.OR

  30. Kanat M. Is daytime insulin more physiologicand less atherogenic than bedtime insulin?Med. Hypotheses. 2007;68(6):1228–1232.https://doi.org/10.1016/j.mehy.2006.10.037

  31. Wang JS, Lee IT, Lee WJ, Lin SD, Su SL, TuST, Lin SY, Sheu WH. The dawn phenomenonin type 2 diabetes: its association withglucose excursions and changes after oralglucose-lowering drugs. TACD. 2021;12,20406223211033674.https://doi.org/10.1177/20406223211033674

  32. Schafer KA. The cell cycle: a review. Vet.Pathol. 1998;35(6):461–478.https://doi.org/10.1177/030098589803500601

  33. Cooper GM. The Cell: A Molecular Approach.2nd edition. Sunderland (MA): SinauerAssociates; 2000. Available from:https://www.ncbi.nlm.nih.gov/books/NBK9963/

  34. Nygren P, SBU-group. Swedish Council onTechnology Assessment in Health Care.What is cancer chemotherapy? Acta Oncol.2001;40(2-3):166–174.https://doi.org/10.1080/02841860151116204

  35. Lévi F, Focan C, Karaboué A, de la Valette V,Focan-Henrard D, Baron B, Kreutz F,Giacchetti S. Implications of circadian clocksfor the rhythmic delivery of cancertherapeutics. Adv. Drug Deliv. Rev.2007;59(9-10):1015–1035.https://doi.org/10.1016/j.addr.2006.11.001




2020     |     www.medigraphic.com